EUVIMEDEUVIMED entdecken
Crossref

Osteoclast-derived DEL1 promotes pathological bone formation in ankylosing spondylitis by regulating RUNX2 expression in osteoblasts

Seung Hoon Lee, Chanhyeok Jeon, Dongju Kim, Hye-Ryeong Jo, Eunae Ko, Jeehee Youn, Seunghun Lee, Sung Hoon Choi, Ye-Soo Park, Sungsin Jo, Tae-Hwan Kim

Differentiation · 2026

DOI: 10.1016/j.diff.2026.100962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Differentiation, 2026. Verfasst von Seung Hoon Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul, 04763, South Korea. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Osteoblasts, Core Binding Factor Alpha 1 Subunit, Osteoclasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by ectopic bone formation. We investigated in vitro and in vivo the role of developmental endothelial locus-1 (DEL1) on new bone formation and determined the association between DEL1 and spinal progression in AS. METHODS: DEL1 levels were measured in plasma and facet joint tissues from patients with AS, and in osteoclast-derived medium. Human osteoblast precursor cells were treated with recombinant DEL1 protein and cilengitide trifluoroacetate, an αvβ3 integrin inhibitor, to evaluate their effects on osteoblast differentiation markers. A curdlan-injected SKG mouse model was used to mimic AS pathogenesis. Three weeks after curdlan injection, recombinant DEL1 protein or cilengitide was administered, and the mice's ankle thickness was assessed. The mice were sacrificed after six weeks, and micro-CT and histological analyses were performed. RESULTS: DEL1 expression significantly increased during osteoclast differentiation, peaked at the terminal stage, and correlated with disease progression in AS mice. Systemic plasma DEL1 levels were not different between patients with AS and the control group, but were positively correlated with structural damage (mSASSS; R = 0.3433, p = 0.0195). DEL1 pro-osteogenic effects were neutralized by cilengitide, which attenuated DEL1-induced RUNX2 expression and matrix mineralization. CONCLUSION: Our findings establish DEL1 as a key osteoclast-derived coupling factor that drives new bone formation in AS. DEL1 promotes pathological bone formation and osteoblast differentiation by signaling through the integrin αVβ3-RUNX2 axis; targeting this pathway may offer a novel approach to prevent structural damage in patients with AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spondylitis, AnkylosingOsteoblastsCore Binding Factor Alpha 1 SubunitOsteoclastsOsteogenesisCell Adhesion MoleculesCarrier ProteinsAnimalsHumansMiceCell DifferentiationMaleFemaleDisease Models, AnimalCalcium-Binding ProteinsGene Expression Regulation

Stichwörter der Autor:innen

Ankylosing spondylitisDevelopmental endothelial locus-1 (DEL1)Integrin αVβ3New bone formationOsteoblast differentiationosteoclast

Substanzen

Core Binding Factor Alpha 1 SubunitRUNX2 protein, humanEDIL3 protein, humanCell Adhesion MoleculesCarrier ProteinsCalcium-Binding Proteins

Autor:innen und Institutionen

  • Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul, 04763, South Korea.
  • Department of Anatomy & Cell Biology, College of Medicine, Hanyang University, Seoul, 04763, South Korea.
  • Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, South Korea.
  • Department of Orthopaedic Surgery, Hanyang University Seoul Hospital, Seoul, 04763, South Korea.
  • Department of Orthopaedic Surgery, Guri Hospital, Hanyang University College of Medicine, Guri, 11923, South Korea.
  • Department of Biology, College of Natural Sciences, Soonchunhyang University, Asan, Chungcheongnam-do, 31538, South Korea. Electronic address: joejo0517@gmail.com.

Förderung

  • Korea Health Industry Development Institute
  • National Research Foundation of Korea

Zitieren

APA

Lee, S. H., Jeon, C., Kim, D., Jo, H. R., Ko, E., Youn, J., Lee, S., Choi, S. H., Park, Y. S., Jo, S., & Kim, T. H. (2026). Osteoclast-derived DEL1 promotes pathological bone formation in ankylosing spondylitis by regulating RUNX2 expression in osteoblasts. Differentiation. https://doi.org/10.1016/j.diff.2026.100962

Vancouver

Lee SH, Jeon C, Kim D, Jo HR, Ko E, Youn J, et al. Osteoclast-derived DEL1 promotes pathological bone formation in ankylosing spondylitis by regulating RUNX2 expression in osteoblasts. Differentiation. 2026. doi:10.1016/j.diff.2026.100962

BibTeX
@article{Lee2026,
  author = {Lee, Seung Hoon and Jeon, Chanhyeok and Kim, Dongju and Jo, Hye-Ryeong and Ko, Eunae and Youn, Jeehee and Lee, Seunghun and Choi, Sung Hoon and Park, Ye-Soo and Jo, Sungsin and Kim, Tae-Hwan},
  title = {Osteoclast-derived DEL1 promotes pathological bone formation in ankylosing spondylitis by regulating RUNX2 expression in osteoblasts},
  journal = {Differentiation},
  year = {2026},
  doi = {10.1016/j.diff.2026.100962}
}
Kostenlos starten →